Effect of hypolipidemic treatment on the composition of bile and the risk or cholesterol gallstone disease;Vliv hypolipidemické léčby na složení žluce a riziko cholesterolové cholelitiázy

Casopis Lekaru Ceskych

Volumn 146, Issue 1, 2007, Pages 24-34

  Žák, Aleš ^a,b   Zeman, M ^a   Hrubant, K ^a   Vecka, M ^a   Tvrzicka E ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b NONE   (Czech Republic)

Author keywords

Bile saturation with cholesterol; Cholesterol cholelithiasis; Dyslipidemia; Hypolipidemic treatment; Risk of cholelithiasis; Secretion of bile lipids

Indexed keywords

BEZAFIBRATE; BILE ACID; CERIVASTATIN; CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; CLOFIBRATE; EZETIMIBE; FENOFIBRATE; FISH OIL; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PHOSPHATIDYLCHOLINE; POLYUNSATURATED FATTY ACID; PRAVASTATIN; RESIN; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; BILE; BILE ACID SYNTHESIS; CHOLESTEROL METABOLISM; CHOLESTEROL STONE; DRUG EFFECT; DYSLIPIDEMIA; GALLSTONE FORMATION; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPOPROTEIN SYNTHESIS; MICELLE; PATHOGENESIS;

ANTILIPEMIC AGENTS; BILE; BILE ACIDS AND SALTS; CHOLELITHIASIS; CHOLESTEROL; HUMANS; RISK FACTORS;

EID: 33846293978     PISSN: 00087335     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Horton, J. D., Bilhartz, L. E.: Gallstone disease and its complications In: Feldman, M., Friedman, L. S., Sleisinger, M. H. (Eds): Sleisinger & Fordtrans's Gastrointestinal and Liver Disease. Pathophysiology/Diagnosis/Management. 7. vyd. Philadelphia, Saunders, 2002, 2380, s. 1065-1090.
2. Cuevas, A., Miquel, J. F., Reyes, M. S. et al.: Diet as a risk factor for cholesterol gallstone disease. J. Am. Coll. Nutr., 2004, 23, s. 187-196.
3. Gotto, A. M., Pownall, H.: Manual of Lipid Disorders. 3. vyd. Philadelphia, Lippincott Williams Wilkins, 2003, 482 s.
4. Carey, M. C., Cahalane, M. J.: Whither biliary sludge? Gastroenterology, 1988, 95, s. 508-523.
5. Berr, F., Schreiber, E., Frick, U.: Interrelationships of bile acid and phospholipid fatty acid species with cholesterol saturation of duodenal bile in health and gallstone disease. Hepatology, 1992, 16, s. 71-81.
6. Kullak-Ublick, G. A., Steiner, B., Meier, P. J.: Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology, 2004, 126, s. 322-342.
7. Vítek, L.: Nové aspekty v patogeneze cholesterolové cholelitiázy. Čas. Lék. čes., 2002, 141, s. 595-600.
8. Desvergne, B., Michalik, L., Wahli, W.: Transcriptional regulation of metabolism B. Transcriptional control of cholesterol homeostasis. Physiol. Rev., 2006, 86, s. 465-514.
9. Botham, K., Bravo, E.: The role of lipoprotein cholesterol in biliary steroid secretion. Studies with in vivo experimental models. Prog. Lipid Res., 1995, 34, s. 71-97.
10. Mardones, P., Quinones, V., Amigo, L. et al.: Hepatic cholesterol and bile metabolism and intestinal absorption in scavenger receptor vlase B I-deficient mice. J. Lipid Res., 2001, 42, s. 170-180.
11. Fuchs, M., Ivancic, B., Miller, O. et al.: Biliary cholesterol hypersecretion in gallstone-suscpetible mice is associated with hepatic upregulation of the high density lipoprotein receptor SRB1. Hematology, 2002, 35, s. 240-242.
12. Kozarksy, K. F., Donahee, M. H., Rigotti, A. et al.: Overexpression of HDL receptor SR-B1 alters plasma HDL and bile cholesterol levels. Nature, 1997, 382, s. 414-417.
13. Hillebrant, C. G., Nyberg, B., Einarrson, K. et al.: Effects of plasma low density lipoprotein - apheresis on the hepatic secretion of biliary lipids in human. Gut, 1997, 41, s. 700-704.
14. Einarrson, K., Ericsson, S., Ewerth, S. et al.: Bile acid sequestrants: mechanism of action on bile acid and cholesterol metabolism. Eur. J. Clin. Pharmacol., 1991, 40 (Suppl. 1), s. S53-S58
15. Jonkers, I. J. A. M., Smelt, A. H. M., Ledeboer, M. et al.: Gall bladder dysmotility: a risk factor for gall stone formation in hypertriglyceridaemia and reversal on triglyceride lowering therapy by bezafibrate and fish oil. Gut, 2003, 52, s. 109-115.
16. Simonen, P., Gylling, H., Miettinen, T. A.: Introducing a new component of the metabolic syndrome: low cholesterol absorption. Am. J. Clin. Nutr., 2000, 72, s. 82-88
17. Simonen, P. P., Gylling, H. K., Miettinen, T. A.: Diabetes contributes to cholesterol metabolism regardless of obesity. Diabetes Care, 2002, 25, s. 1511-1515.
18. Simonen, P. P., Gylling, H., Miettinen, T. A.: Body weight modulates cholesterol metabolism in non-insulin dependent typ 2 diabetics. Obesity Res., 2002, 5, s. 328-335.
19. Gylling, H., Tuominen, J. A., Koivisto, V. A. et al.: Cholesterol metabolism in type 1 diabetes. Diabetes, 2004, 53, s. 2217-2222.
20. Voshol, P. J., Havinga, R., Wolters, H. et al.: Reduced plasma cholesterol and increased fecal sterol loss in multidrug resistance gene 2 P-glycoprotein-deficient mice. Gastroenterology, 1998, 114, s. 1024-1034.
21. Grundy, S. M., Mok, H. Y. I., Zech, L. et al.: Influence of nicotinic acid on metabolism of cholesterol and triglycerides. J. Lipid Res., 1981, 22, s. 24-36.
22. Angelin, B., Ericsson, M., Einarsson, K.: Combined treatment with cholestyramine and nicotinic acid in heterozygous familal hypercholesterolaemia: effects on biliary lipid composition. Eur. J. Clin. Invest., 1986, 16, s. 391-396.
23. Meyers, C. D., Kamanna, V. S., Kashyap, M. L.: Niacin therapy in atherosclerosis. Curr. Opin. Lipidol., 2004, 15, s. 659-665.
24. Merck Information on Ezetimib. PharmaNote, 2003, 18 s.
25. Report of Committtee of WHO Principal Investigators. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to košer serum cholesterol: mortality folow-up. Lancet, 1980, 2, s. 379-385.
26. Alegret, M., Verd, J. C., Díaz, C. et al.: Effect of hypolipidemic drugs on the key enzyme activities related to lipid metabolism in normolipidemic rabbits. Eur. J. Pharmacol., 1998, 347, s. 283-291.
27. Odman, B, Ericsson, S., Lindmark, M. et al.: Gemfibrozil in familial combined hyperlipidemia: effects of added low-dose cholestyramin on plasma and biliary lipids. Eur. J. Clin. Invest., 1991, 21, s. 344-349.
28. Angelin, B., Einarrson, K., Leijd, B.: Effects of ciprofibrate treatment on biliary lipids in patiens with hyperlipoproteinemia. Eur. J. Clin. Invest., 1984, 14, s. 73-78.
29. Caroli-Bosc, F.-X., Le Gall, P., Pugliese, P. et al.: Role of fibrates and HMG-CoA reduktase inhibitors in gallstone formation. Epidemiological study in an unselected population. Dig. Dis. Sci., 2001, 46, s. 540-544.
30. Smith, J. L., Nathanson, L. K., Riottot, M.: Effect of statins n biliary lipids and cholesterol gallstones. J. Cardiol., 2002, 9, s. 295-298.
31. Carrella, M., Feldman, D., Cogol, S. et al.: Enhancement of mdr2 gene transcription mediates the biliary transfer of phosphatidylcholine supplied by an increased biosynthesis in the pravastatin-treated rat. Hepatology, 1999, 29, s. 1825-1832.
32. Hrabák, P., Žák, A., Zeman, M. et al.: Příznivý vliv dietnich omega-3 polyenových mastných kyselin na litogenitu žluče u endogenní hypertriglyceridémie. Vnitř. Lék., 1988, 34, s. 701-708.
33. Berr, F., Holl, J., Jüngst, D. et al.: Dietary n-3 polyunsaturated fatty acids decrease biliary cholesterol saturation in gallstone disease. Hepatology, 1992, 16, s. 960-967.
34. Méndez-Sánchez, N., González, V., Aguayo, P. et al.: Fish oil (n-3) polyunsaturated fatty acids beneficially effects biliary cholesterol nucleation time in obese women losing weight. J. Nutr., 2001, 131, s. 2300-2303.
35. Carey, M. C., Cahalane, M. J.: Enterohepatic circulation. In: Arias, I. M., Jakoby, W. B., Popper, H. et al. (Eds): The liver: biology and pathobiology. New York, Raven Press, 1988, s. 573-616.
36. Basciano, H., Federico, L., Adeli, K.: Fructose, insulin resistance, and metabolic dyslipidemia. Nutr. Metab. (London), 2005, 2, s. 5.
37. Ericsson, S, Ericsson, M., Angelin, B.: Biliary lipids in familial combined hyperlipidemia: effects of acipimox therapy. Eur. J. Clin. Invest., 1990, 20, s. 261-265.